Marathon Pharmaceuticals

Muscular dystrophy drug launch halts after pricing concernsMarathon Pharmaceuticals is temporarily pausing the launch of its drug to treat a rare form of muscular dystrophy (MD) after concerns over its $89,000 price tag.
FDA drug approvals-January 2015FDA actions in brief, recommendations for approval, fast-track designations.